Pharmafile Logo
Pharmafocus logo
Advanced Search

ea pharma

Showing 2 posts of 2 posts found.

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026
Research and Development Psychiatry, ea pharma, schizophrenia

EA Pharma, a subsidiary of Eisai, has announced the initiation of a phase 3 clinical trial of evenamide, a schizophrenia …

News
ea_pharma

Eisai announces agreement to set up new gastrointestinal speciality company

March 30, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Ajinomoto, Eisai, absorption, acquisition, ea pharma, gastrointestinal, merger, speciality

Eisai (TYO: 4523) and Ajinomoto Co. (TYO: 2802) have announced an agreement to establish a new gastrointestinal speciality pharmaceutical company, …

News
The Gateway to Local Adoption Series

Latest content

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026

Alvotech appoints Lisa Graver as CEO

February 3, 2026

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026